|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of TNF-α inhibitors in patients with psoriasis and metabolic syndrome: a preliminary study.
|
28421729 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy has revolutionized the treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis.
|
31719235 |
2020 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, the conjugate exhibited an improved antiproliferation activity in tumor necrosis factor-α-induced HaCaT cells, which is an in vitro psoriasis model.
|
31751564 |
2020 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis.
|
30916734 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF inhibitors are also efficacious for other inflammatory joint and spine diseases, and have been approved for inflammatory bowel disease, uveitis and psoriasis.
|
31639514 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis.
|
31017250 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, IL-17A and TNF-α in PSO patients were negatively associated with the Gαq expression.
|
30654308 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In case of a severe course of psoriasis and moderate-to-severe disease in which traditional systemic treatments are ineffective or contraindicated, TNF-α inhibitors (iTNF-α) are used.
|
30288872 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical success of biologics that inhibit TNF (Tumor Necrosis Factor) in inflammatory bowel diseases (IBD), psoriasis and rheumatoid arthritis (RA) has clearly established a pathogenic role for this cytokine in these inflammatory disorders.
|
31457011 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF) α which releases from keratinocytes activates dendritic cells in the early stages of complex pathogenesis of psoriasis.
|
30972872 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.
|
31424708 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings confirm the importance of TNF-α in psoriasis pathogenesis and a positive correlation with lesions severity.
|
31384319 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α‑stimulated HaCaT cells and an imiquimod‑induced psoriasis mouse model were used to produce in vitro and in vivo models, respectively.
|
31017270 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The main signalling pathways in psoriasis include TNF-α, IL-23 and IL-17.
|
31639088 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with GRg1 or DXM significantly mitigates (p < .01) psoriasis area severity index (PASI) score, skin thickness, lipid peroxidation, and inflammatory markers (IL-23, 22, 17A, 1β, and TNF-α).
|
31502279 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors.
|
30515970 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we elucidate the cellular and molecular "scar" and its imprints left after clinical resolution of psoriasis treated with anti-TNFα, anti-IL-17, or anti-IL-23 antibodies or phototherapy.
|
31673756 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To inform biomarker discovery in the Psoriasis Stratification to Optimise Relevant Therapy (i.e., PSORT) study, we evaluated a comprehensive array of omics platforms across three time points and multiple tissues in a pilot investigation of 10 patients with severe psoriasis, treated with the tumor necrosis factor (TNF) inhibitor, etanercept.
|
30030151 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, other disease-specific variables showed no statistical significance: gender (P = 0.286), peripheral arthritis (P = 0.634), enthesitis (P = 0.464), dacylitis (P = 0.750), psoriasis (P = 0.552), inflammatory bowel disease (P = 0.369), human leukocyte antigen-B27 positivity (P = 0.473), use of non-steroidal anti-inflammatory drugs (P = 0.448), and use of tumor necrosis factor-blocker in the last 3 months (P = 0.505).
|
30729703 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this report, we describe a case of a patient with a clinical history of systemic sarcoidosis and psoriasis who developed biopsy-confirmed perforating and necrotizing cutaneous granulomas after 12 months of treatment with adalimumab, a tumor necrosis factor-alpha-inhibiting, anti-inflammatory, biologic medication, prescribed for the patient's psoriasis.
|
30839343 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the past decade, biologics targeting tumor necrosis factor-α, interleukin (IL)-23, and IL-17 have been developed and approved for the treatment of psoriasis.
|
31491865 |
2019 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The excellent response of psoriasis to anti-TNF-α(TNF)/IL23/IL17A biologics implies a crucial role for the TNF/IL23/IL17 axis in developing psoriasis.
|
30648836 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |